Ads
related to: Abbvie- Supporting Our Workforce
Embracing Equality & Diversity
Makes Us More Innovative.
- Read AbbVie Stories
Read Stories About Our Science,
People, and More Today.
- AbbVie News Center
See Our Achievements, Growth Story,
and More Today.
- Investor Resources
Find Financial Reports, Stock Info
And More Resources For Investors.
- Supporting Our Workforce
Search results
Waterloo Capital L.P. Buys 10,333 Shares of AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 7 days agoWaterloo Capital L.P. grew its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 571.2% in the fourth quarter, according to the company in its most recent filing with the ...
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory...
The Port Lavaca Wave· 3 days ago- Global license agreement to focus on the development of FG-M701, a TL1A antibody, for the treatment of inflammatory bowel disease (IBD)
Heads Up: Abbvie's Migraine Portfolio 'Very, Very Strong'
MediaPost· 3 days agoIn the wake of Abbvie’s loss of exclusivity for its blockbuster Humira anti-inflammatory drug, its migraine-fighting meds -- Ubrelva, Qulipta and Botox -- have emerged as ...
AbbVie Signs On To Recruit Diverse Talent at Upcoming HBCU Connect Annual Conference & Career Fair...
BlackNews.com· 2 days agoOn Friday, June 28th, 2024 at Washington Nationals Stadium in Washington, DC, HBCU CONNECT will host...
...Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails - AstraZeneca...
Benzinga· 1 day agoPfizer's PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for...
AbbVie inks immune disorder drug licensing deal with China's FutureGen
AOL· 3 days agoAbbVie has been counting on its newer immunology medicines to help make up for declining sales of blockbuster arthritis drug Humira following the entry of biosimilars in the ...
AbbVie inks deal potentially worth $1.7 billion for new IBD drug
Crain s Chicago Business· 3 days agoAbbVie's latest move in inflammatory bowel disease treatments is a licensing agreement to develop a next generation antibody engineered by Beijing-based FutureGen. The terms ...
AbbVie joins TL1A race via $150M upfront deal with China's FutureGen
FierceBiotech· 3 days agoAbbVie has become the latest Big Pharma to jump on the anti-TL1A train, paying China’s FutureGen Biopharmaceutical $150 million upfront for a preclinical inflammatory bowel ...
Digital Medicine Society partners with pharma giants for new digital endpoints project
FierceBiotech· 3 days agoAbbvie, Merck, Roche, Genentech, Regeneron, Sanofi and other big names in biopharma have signed on...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Zacks via Yahoo Finance· 2 days agoThe FDA approved AstraZeneca’s AZN type-II diabetes (T2D) medicine, Farxiga, for pediatric patients....
Ad
related to: Abbvie